Scientists collect kidney samples from COVID-19 patients to uncover clues about organ damage

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients 18 years of age or older admitted to participating hospitals with a positive COVID-19 test result or Persons Under Investigation with suspected COVID-19 infection AND with AKI or at high risk of AKI in the setting of COVID-19 infection, as defined by any ONE of the following: * pre-existing chronic kidney disease as defined by eGFR less than 60 ml/min/1.73 m2 * history of diabetes mellitus established by at least one of the following criteria: * Hemoglobin A1C greater than or equal to 6.5%, confirmed with a repeat test within the past year * Fasting blood sugar greater than or equal to 126 mg/dL, confirmed with a repeat test within the past year * Use of glucose-lowering therapy (insulin or oral or other subcutaneous agents) * International Classification of Diseases (ICD) 9/10 diagnostic code for diabetes * requiring use of vasopressors * requiring use of mechanical ventilation AKI is defined by temporal changes in serum creatinine meeting KDIGO Stage 1 criteria or greater (0.3 rise in serum creatinine over baseline value). If a baseline serum creatinine is not available, the patient can be enrolled with an estimated Baseline serum creatinine (see KPMP COVID-19 Manual of Procedures table 1) Exclusion Criteria: Any potential participant meeting any one of the general or safety exclusion criteria will not be eligible for enrollment in the KPMP COVID-19 Substudy. Exclusion criteria include non-transient conditions that would not allow for enrollment in the main KPMP study. Determined at time of Eligibility Assessment prior to consent: * Non-English or Spanish language * Less than 18 years of age * Severe allergy to iodinated contrast * Transplant recipient (kidney or non-kidney, including solid organ and bone marrow transplantation) * Additional vulnerable individuals (incarcerated, institutionalized, or otherwise unable to participate in the study) * Inability to provide informed consent or obtain surrogate consent from a legally authorized representative (LAR) * Unwilling to receive blood transfusion (if needed) * Baseline eGFR less than 15 ml/min/m2 If known at the time of enrollment, or determined by kidney ultrasound before the biopsy procedure (may be the same day as the biopsy procedure) * Kidney size less than 8 cm (percutaneous biopsies only) * Solitary or single functioning kidney * Evidence of urinary tract obstruction or hydronephrosis * Multiple bilateral kidney cysts